An Anti-ICAM-2 (CD102) Monoclonal Antibody Induces Immune-mediated Regressions of Transplanted ICAM-2-negative Colon Carcinomas

Igancio Melero, Izaskun Gabari, Angel L. Corbi, Miguel Relloso, Guillermo Mazzolini, Volker Schmitz, Mercedes Rodriguez-Calvillo, Iñigo Tirapu, Emilio Camafeita, Juan P. Albar, and Jesús Prieto

Gene Therapy Unit, Department of Medicine, University of Navarra School of Medicine, 31008 Pamplona [I. M., I. G., G. M., V. S., M. R.-C., I. T., J. P.]; Proteomics Facility and Department of Immunology and Oncology, Centro Nacional de Biotecnología (Pharmacal/Consejo Superior de Investigaciones Científicas), Canto Blanco, E-28049 Madrid (E. C., J. P. A.); and Centro de Investigaciones Biológicas, Consejo Superior de Investigaciones Científicas, 28006 Madrid [A. L. C., M. R.] Spain

ABSTRACT

Monoclonal antibodies (mAbs) can mediate antitumor effects by indirect mechanisms involving angiogenesis and up-regulation of the cellular immune response rather than by direct tumor cell destruction. From mAbs raised by immunization of rats with transformed murine endothelial cells, a mAb (EOL4G8) was selected for its ability to eradicate a fraction of established colon carcinomas that did not express the EOL4G8-recognized antigen. The antigen was found to be ICAM-2 (CD102). Antitumor effects of EOL4G8, which required a functional T-cell compartment, were abrogated by depletion of CD8+ cells and correlated with antitumor CTL activity, whereas only a mild inhibition of angiogenesis was observed. Interestingly, we found that EOL4G8 acting on endothelial ICAM-2 markedly enhances leukotactic factor activity-1-independent adhesion of immature dendritic cells to endothelium—an effect that is at least in part mediated by DC-SIGN (CD209).

INTRODUCTION

mAbs1 have been used to inflict selective damage to malignant cells in vivo both in animal experimentation and at the clinic (1). More recently, mAbs have been used to elicit indirect mechanisms that efficiently treat tumors by potentiating the immune response (2–4) or by decreasing angiogenesis in the malignant tissue (5, 6).

To identify novel antibody specificities that could operate through these indirect mechanisms, we immunized rats with mouse endotheloma cells and searched for mAbs displaying antitumor effects in vivo. We found one antibody fulfilling such features that recognized the adhesion molecule ICAM-2 (CD102). This surface antigen is a glycoprotein that belongs to the Ig superfamily encompassing two Ig domains (7–9). It was functionally identified in humans as a counter-receptor for the leukocyte integrin LFA-1 (8). Tissue distribution for ICAM-2 in humans includes constitutive expression on endothelial cells as well as on T and B lymphocytes (7). Recently a second counter-receptor for ICAM-2 has been identified selectively expressed on human DCs, and that molecule is the C-type lectin named DC-SIGN (CD209) (Ref. 10). This lectin was originally described in dendritic cells (DCs) primarily expressing the molecule MR-1 (11). A number of DC-SIGN murine homologues have been identified recently, but information on its function is not available yet, although one of the homologues is expressed in DCs at the RNA level (12). ICAM-2+/+ mice develop normal immune responses and accordingly the function of this molecule is largely dispensable (13), indicating that its function is probably redundant with other proteins of its family.

This study demonstrates that in vivo treatment with anti-ICAM-2 mAbs can cure established transplanted colon carcinomas that are completely ICAM-2-negative through mechanisms that are dependent on the induction of tumor-specific CTL-mediated immune responses. Evidence has been obtained that ICAM-2 bound by EOL4G8 up-regulates its adhesiveness to DC-SIGN, providing a mechanistic rationale to the enhancement of antitumor immunity.

MATERIALS AND METHODS

Cell Lines, Antibodies, and Reagents. MC38 and CT26 have been described previously (18). PY-4.1 and H5V are SV40 T-transformed endotheliomas (19, 20) generously given by V. Bautch (University of North Carolina, Chapel Hill, NC) and A. Mantovani (Instituto Mario Negri, Milan, Italy). These cells have been derived from transgenic mice ubiquitously expressing SV40 T antigen. D2SC/1 is a spleen-derived murine DC line (kindly provided by P. Ricciardi-Castagnoli, University of Milan, Italy; Refs. 21, 22). Human DC-SIGN-expressing transfectants in K562 cells and the anti DC-SIGN mAb (MR-1) have been described (23). 3C8 antituine ICAM-2 was from PharMingen (Heidelberg, Germany) as well as anti-ICAM-1, anti-VCAM-1, anti-H-2L, anti-H-2K, anti-CD3 anti-CD28, anti-LFA-1, anti-CD31, and secondary FITC-tagged antirat IgG and IgG2b antibodies. Hybridoma production and purification of EOL4G8 mAb was as described (24). The screening was performed by selecting out antibodies binding PY-4.1 but not various carcinoma cell lines. Hybridomas fulfilling both criteria were grown as ascites in BALB/c-nu/nu mice, and ascites fluid was tested for in vivo interference of CT26-derived tumors implanted in syngeneic mice by giving it inside tumor nodules. Anti-CD8-depleting antibody was ascitic fluid of the hybridoma H35–17.2 (American Type Culture Collection; Ref. 25). TS2.18 antianhuman CD18 was from Francisco Sanchez-Madrid (Hospital de la Princesa, Spain). Antibody-conjugated magnetic beads and cell separation protocols were from Miltenyi (Bergisch Gladbach, Germany), Rat IgG, Colchicine, ConA, and EGTa were from Sigma (Madrid, Spain). Culture medium and FCS were from Life Technologies, Inc. (Cergy-Pontoise, France).

Flow Cytometry and Immunohistochemistry. Indirect and direct immunofluorescence and flow cytometry were performed as described (24) using a FACScalibur (Becton Dickinson, Mountain View, CA). Cryosections were prepared and processed for indirect immunohistochemical staining as described (24).

Immunoprecipitation and Western Blot. PY4.1 cells were surface biotinylated with sulfo-NHS-Biotin (Pierce, Rockford, IL), lysed, and immunoprecipitates were obtained as described (24, 26). Immunoprecipitates were analyzed by SDS-PAGE, transferred onto a polyvinylidene difluoride membrane (Immobilon-P; Millipore, Bedford, MA), and developed with streptavidin-peroxidase (streptavidin-HPR; Pierce) and chemiluminescence (ECL; Amersham-Pharmacia, Barcelona, Spain; Ref. 24). Western blotting with

Received 11/26/01; accepted 4/2/02.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 Supported by CICYT (SAI 99-0039), Gobierno de Navarra, Fundación Española de Hematología y Hemoterapia, Fundación Ramón Arceces and Familia Vidal-Huarte. The Department of Immunology and Oncology at Centro Nacional de Biotecnología was founded and is supported by the Spanish Research Council (Consejo Superior de Investigaciones Científicas) and Pharmacia Corporation.

2 To whom requests for reprints should be addressed, at Department of Medicine, Facultad de Medicina, Universidad de Navarra, C/Inramarea, 1, 31008 Pamplona, Spain. E-mail: imelero@unav.es.

3 The abbreviations used are: mAb, monoclonal antibody; Ig, immunoglobulin; LFA, leukotactic factor activity; DC, dendritic cell; DC-SIGN, dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin; ICAM, intercellular adhesion molecule; PSD, postsecretion decay; MALDI, matrix-assisted desorption ionization; VEGF, vascular endothelial growth factor; bFGF, basic fibroblast growth factor; ConA, concanavalin A; FACS, fluorescence-activated cell sorter.

3167

Downloaded from cancerres.aacrjournals.org on April 13, 2017. © 2002 American Association for Cancer Research.
EOL4G8 was performed as described (25) with ascites 1/1000 or 5 μg/ml of purified mAb in blocking solution.

Affinity Chromatography, SDS-PAGE, and In-Gel Digestion of Proteins. Purified EOL4G8 was covalently bound to Sepharose beads (CNBr-activated Sepharose; Amersham-Pharmacia-Biotech) according to the manufacturer’s protocols. Columns were packaged in 2-ml syringes and, after conditioning with extensive washing with PBS, were loaded with PY-4.1 cell lysate from 10^9 cells in PBS with 1% Triton Tx-100 containing phenylmethysulfonyl fluoride, aprotinin, and leupeptin (Sigma). Optimal elution buffer was 1 M Tris (pH 12), and 0.5-ml fractions were collected. Concentrated fractions (Centricron; Millipore, Madrid, Spain) were run in 12% SDS-PAGE, and stained protein bands were excised from the gel and then processed automatically using an Investigator ProGest protein digestion station (Genomic Solutions, Cambridgeshire, United Kingdom). Peptides were eluted with acetonitrile, 25 mM ammonium bicarbonate, and 10% formic acid (v/v) for a final extraction volume of 100 μl.

MALDI Peptide Mass Fingerprinting, Database Searching, and PSD MALDI Analysis. A 0.5-μl aliquot of the extraction solution was used to measure automatically the mass fingerprint on a Bruker Reflex III MALDI-time of flight mass spectrometer (Bruker-Franzen Analytic GmbH, Bremen, Germany) in positive ion reflector mode using delayed extraction. The measured tryptic peptide masses were transferred automatically through the MS BioTools program as inputs to search automatically the National Center for Biotechnology Information database using Mascot software (Matrix Science, London, United Kingdom). The PSD MALDI spectrum was recorded automatically, and the precursor ion was selected by FAST deflecting pulses. Data analysis was performed using Bruker BioTools 2.0 software.

Mice and in vivo Experimentation. Female C57BL/6, BALB/c, and BALB/c-nc/nu mice (6–12 weeks old) were purchased from Jackson (Barcelona, Spain). A breeding pair of Rag2−/− mice was obtained from T. Rolink (Basel Institute for Immunology, Basel, Switzerland; Ref. 27) and bred in our animal facility. s.c. tumors were obtained by injection of 5 × 10^6 MC38 in C57BL/6 mice (18), or 1 × 10^7 PY4.1 cells in BALB/c-nc/nu mice (19), and monitored as described (25). s.c. Matrigel plugs were implanted by injection of ice-cold Matrigel containing 10 ng/ml VEGF and 10 ng/ml bFGF (Peprotech, London, United Kingdom). Ten days later, plugs and surrounding tissue were paraffin-embedded and H&E stained. Endothelial cells with lumens per microscopic field (>200) were counted in at least 5 fields/section and 5 sections/Matrigel plug (identity of endothelium was confirmed by immunohistochemistry with anti-Von Willebrand factor in serial sections; Refs. 25, 28, 29).

CTL Studies and ELISAs. Standard 51Cr release were done on CT26 and P815 cells as target cells using spleen cells restimulated in vitro with Mytomycin-C-treated CT26 cells at a 10:1 ratio as described (25, 30).

Adhesion Experiments. Human monocyte-derived DCs and mouse bone marrow-derived DCs were obtained as described (18, 31). PY-4.1 cells were seeded in flat-bottomed 96-well plates and cultured in DMEM 10% FCS until confluence was reached. Then FCS was washed, and mAbs and 8 × 10^4 DCs in serum-free DMEM were added and incubated for 90 min under rotation at 60 rpm. Wells were subsequently washed five times with prewarmed DMEM, and attached DCs were counted under phase contrast microscopy in defined surfaces with a grid. Four equally placed surfaces were counted per well by an operator blinded to the experiment.

RESULTS

Obtainment, Selection, and Characterization of the EOL4G8 mAb. To obtain mAbs, rats were immunized with mouse endothelial cells derived from hemangiomas raised in SV40T-transgenic mice (19, 20). A primary screening was set up to search for antibodies that could bind surface proteins on murine endothelioma cells but not on a wide panel of cell lines of epithelial origin. Thus, selected antibodies were screened for in vivo antitumoral effects. The antibody produced by the hybridoma EOL4G8 (rat IgG2b) fulfilled both criteria. As it can be seen in Fig. 1, a and b, EOL4G8 brightly stained the cell surface of two endothelioma cell lines that coexpressed endothelial lineage and activation markers such as CD31, CD34, the αvβ3 integrin, ICAM-1, ICAM-2, and VCAM-1.

By contrast as shown in Fig. 1, c and d, EOL4G8 completely failed to detect antigens on the surface of the colon carcinoma cell lines CT26 and MC38 that were MHC class I-positive. EOL4G8 immunoprecipitated a single band of 59 kDa (Fig. 1e) on reducing and nonreducing conditions from lysates that had been obtained from the endothelioma cell line PY-4.1.

Immunohistochemical analysis of BALB/c livers harboring CT26-derived experimental metastasis showed a pattern of stromal staining.
in vascular structures with lumen (Fig. 1, f–h). Positive cells were confirmed to be endothelial by positive immunostaining of serial sections with anti-CD31 mAb (not shown). It should be noted that the number of EOL4G8/H11001 cells in tumor stroma was outnumbered by at least 3-fold by CD31/H11001 cells, indicating that not every endothelial cell in the malignant tissue was EOL4G8/H11001 (not shown). Interestingly, these immunohistochemical analyses did not detect any cells of healthy liver including sinusoidal and nonsinusoidal vascular structures. Positive staining with EOL4G8 mAb was also found in many vascular structures within skeletal muscle (Fig. 1, i).

Fig. 2. EOL4G8 mAb recognizes murine ICAM-2 (CD102). a, MALDI fingerprinting analysis of the band in fraction 2 (visualized in the figure by Western blot with EOL4G8 mAb and marked with a dotted arrow), as it was obtained from PY-4.1 lysates using affinity chromatography columns packaged with Sepharose covalently linked to EOL4G8 mAb and analyzed subsequently by SDS-PAGE. Scores obtained on computer assisted comparison of the molecular masses of the tryptic peptides with those present in the National Center for Biotechnology Information database are summarized in the table included. b, 12% SDS-PAGE of immunoprecipitates obtained with commercial 3C8 anti-ICAM-2 mAb, anti MECA-32 mAb (negative control), or with EOL4G8 mAb that were developed in Western blot by EOL4G8 mAb. c, PSD MALDI analysis of the peak indicated by the arrow in a, which yields a fragment ion spectrum compatible with the sequence (detailed in the figure) proposed for that peak.

in vascular structures with lumen (Fig. 1, f–h). Positive cells were confirmed to be endothelial by positive immunostaining of serial sections with anti-CD31 mAb (not shown). It should be noted that the number of EOL4G8+ cells in tumor stroma was outnumbered by at least 3-fold by CD31+ cells, indicating that not every endothelial cell in the malignant tissue was EOL4G8+ (not shown). Interestingly, these immunohistochemical analyses did not detect any cells of healthy liver including sinusoidal and nonsinusoidal vascular structures. Positive staining with EOL4G8 mAb was also found in many vascular structures within skeletal muscle (Fig. 1i), whereas only a
minority of vascular structures (mainly arteriolas) were detected in brain, eye, testis, heart, and lung tissue (not shown).

On PY-4.1 cells the antigen recognized by EOL4G8 evenly decorated the plasma membrane on indirect immunofluorescence staining (Fig. 1j), but it underwent capping at 37°C for 20 min (Fig. 1k) and internalization at later time points (Fig. 1l).

Affinity chromatography with EOL4G8 mAb purified the membrane protein from PY-4.1-derived cell lysates. Elution fractions could be followed by Western blot with EOL4G8. Fraction F2 (indicated with a dotted arrow in Fig. 2a) was concentrated, run in SDS-PAGE, and the excised band was subjected to trypic peptide fingerprinting analysis by MALDI. The database search using trypic peptide masses observed in the MALDI peptide fingerprinting (Fig. 2a) proposed the intercellular adhesion protein-2 from mouse as a top candidate as shown in the score table under Fig. 2a.

Furthermore, immunoprecipitates obtained with a commercial antitumor ICAM-2 mAb (3C8; Ref. 9) were recognized in Western blot analysis by EOL4G8 mAb depicting a band with identical electrophoretic mobility to that immunoprecipitated by EOL4G8 itself (Fig. 2b). Identification was additionally confirmed by MALDI-PSD analysis. Fig. 2c shows a recorded series of y-, a-, and b-type fragment ions generated by decomposition of the peptide at m/z = 1194.64 (peak) in the mass fingerprinting spectrum, which are compatible with its putative sequence. Molecular weight of 31.8 kDa from the predicted peptide backbone indicates heavy glycosylation if compared with the estimated 59 kDa in SDS-PAGE analysis of immunoprecipitates.

Antitumor Effects of EOL4G8 Anti-ICAM-2 mAb. Experiments shown in Table 1 demonstrate that in vivo administration of EOL4G8 mAb to mice bearing established s.c. tumors derived from the injection of CT26 or MC38 cells resulted in complete regressions in an important fraction of cases. In this series of experiments the antibody was given either as ascites fluid or as purified protein. Three doses repeated every third day of 100 μl of ascites or 150 μg of purified antibody were chosen. In the first two experiments EOL4G8 was injected inside the malignant nodule in an attempt to reach high local concentrations in the tumor environment. Treatment of CT26 tumors was started on day 7 or 8 after tumor inoculation when tumor nodules rank from 4 to 7 mm (mean diameter). Injection of purified EOL4G8 mAb through i.p. route at similar doses and dosing schedule induced complete regressions in a comparable fraction of tumors, indicating that the intratumoral route was not required. All of the tumor regressions were sustained during at least 6 months without obvious signs of tumor relapses or toxicity related to treatment.

Similar experiments were undertaken with MC38-derived tumors. In this case the effects were not curative if the onset of the i.p. regime of EOL4G8 mAb was postponed until day 7. However, two tumors of six cases completely regressed if the treatment course started on day 5. Moreover, when i.p. treatment immediately followed MC38 tumor cell inoculation, three cases of four mice underwent complete regression after transient detectable tumor growth.

Surprisingly, no antitumor activity against CT26 s.c. tumors was detected in immunodeficient BALB/c-nu or Rag2<sup>-/-</sup> mice (in BALB/c background) suggesting a role of the immune system in the observed phenomenon.

Mechanisms Involved in EOL4G8 Antitumor Activity. Addressing this immune system involvement, we found that weekly depletion of CD8 cells with specific mAbs eliminated the antitumor effects of EOL4G8 (Fig. 3, a and b). Depletion of CD4 cells in a similar type of experiment did not exert a significant effect on the outcome of EOL4G8 mAb treatment (not shown). In accordance, we found in two experiments that 20 days after EOL4G8 treatment the spleen of mice bearing CT26 s.c. tumors had specific antitumor CTL activity (Fig. 3c) that was not detected in mice treated with control antibody. Furthermore, tumors 7 days after treatment showed a prominent infiltrate of mononuclear cells (especially around vessels) also with some granulocytes, including eosinophils and areas of tumor necrosis (Fig. 3d).

Resting murine T lymphocytes expressed barely detectable levels of ICAM-2 but concanavalin + interleukin 2 stimulated T lymphoblasts readily expressed this molecule with high intensity (Fig. 3e, f). Therefore, a potential way of action of the antibody was to provide costimulatory signals to activated ICAM-2<sup>-/-</sup> antitumor T cells. Nonetheless we could not demonstrate any activity of EOL4G8 mAb to provide costimulation to suboptimal stimulation with anti-CD3 antibodies in vitro either to induce proliferation or IFN-γ secretion, regardless of the extensive series of experimental conditions under which anti-CD28 used as a positive control readily costimulated these effects (not shown). Those conditions included rested T-cell blasts that intensely expressed ICAM-2 and mixed lymphocyte culture-type cultures of T cells and fully allogeneic DCs. In both cases EOL4G8 mAb, either attached to plastic or in soluble form, failed to modify the response to suboptimal anti-CD3 mAb or alloantigens.

We carried out experiments to assess a potential antiangiogenic effect of this antibody although the antitumor activity could not be explained solely by antiangiogenesis because it was not found in immunodeficient mice. The subject was studied by implanting Matrigel plugs embedded in VEGF + bFGF in nude mice and assessing the number of endothelial cells in microscopic fields within the Matrigel plug. An inhibition (≈ 30%) induced by EOL4G8 mAb was found in comparison with mice treated with control antibodies (Fig. 3g). Furthermore, EOL4G8 was able to decrease the rate of progression of PY-4.1-derived hemangiommas in nude mice indicating the ability of the antibody to interfere in vivo with the growth of these ICAM-2<sup>-/-</sup> transformed endothelial cells (Fig. 3h).

EOL4G8 mAb Provokes Attachment of DCs to ICAM-2<sup>-/-</sup> Endothelial Cells. Incubation of PY-4.1 cells in vitro with EOL4G8 did not result in changes in cell viability, morphology, proliferation, or tubulization on Matrigel. However, we found that preincubation of a monolayer of PY-4.1 with EOL4G8 induced the adhesion to it of a DC line (D2SC/1) that represents DCs at an immature status (Ref. 21; Fig. 4a). This effect was not observed with control antibodies including a commercially available antimurine ICAM-2 antibody (3C8). The increased adhesion was not blocked by an anti-LFA-1 mAb that inhibits
Fig. 3. Treatment with EOL4G8 mAb stimulates antitumor CTL-mediated immune responses and can interfere with endothelial cells in vivo. a, follow-up of tumor mean diameters of CT26 tumors in mice receiving 150 µg i.p. of EOL4G8 mAb on days 7, 10, and 12 after tumor inoculation. b, similar to a, but in this case mice received 100 µl of ascites containing depleting anti-CD8 mAb on days 6, 14, and 21 after tumor inoculation. c, CTL activity against CT26 in a 4-hour 3Cr release assays of splenocytes obtained from mice bearing s.c. CT26 tumors treated on days 7, 10, and 12 with 150 µg of EOL4G8 or control rat IgG. Results from two independent experiments with two mice/group are shown. Specificity was checked by lack of cytolytic activity against P815 cells in experiments performed in parallel (not shown). d, H&E staining of sections obtained from a representative s.c. CT26 tumor taken 14 days after tumor cell inoculation once mice had received treatment with two doses of 150 µg of EOL4G8 mAb given on days 6 and 8. A (×100) magnification field is shown with a detail (×200) shown in the top right corner of the picture. Eosinophils are indicated by the arrows: e and f, expression of ICAM-2 as detected by EOL4G8 and FACS analysis in magnetic bead-purified T cells from normal resting BALB/c spleens containing 29% CD8+ cells and 60% CD4+ cells (e) and in those lymphocytes after activation with 2 µg/ml of ConA plus 500 IU of human recombinant interleukin 2 for 4 days (f). Results were confirmed with the 3C8 anti ICAM-2 mAb (not shown). g, vascularization of Matrigel implants embedded in VEGF and bFGF placed under the skin of BALB/c nude mice that received 150 µg of EOL4G8 or control antibody on days 0 and 3 after Matrigel injection, measured as the number of endothelial cells in microscopic fields (×200) from H&E-stained sections. Four Matrigel plugs were implanted in each mouse with a total of seven mice/group, and data are from five sections from each plug. Statistical significance was P < 0.01 according to Student’s t test. h, sequential hemangioma growth (assessed by mean diameter in mm) under the skin of BALB/c mice treated on days 7, 10, and 12 with 150 µg of EOL4G8 mAb or control rat IgG (150 µg/p. done) on days 3, 6, and 9; bars, ±SD.

its binding to ICAM-1 and remained unaffected by an antibody that also binds a surface molecule of endothelial cells (anti-MECA-32). The augment of cell adhesion took place at 4°C and when soluble nonattached mAb had been removed indicating that this phenomenon did not require active metabolism nor direct access of soluble antibody to the DC line (Fig. 4a). Furthermore, EOL4G8 mAb was able to promote adhesion of DCs to affinity-purified PY-4.1-derived ICAM-2, showing that enhancement of adhesion took place irrespective on whether ICAM-2 was or was not attached to a cell surface (Fig. 4b). D2SC/1 also expresses low levels of ICAM-2 and, therefore, EOL4G8 could be acting on the DC side. (Fig. 4c). EOL4G8-induced adhesion is dependent on divalent cations because it is inhibited by EGTA (Fig. 4d) and is dependent on the tubulin cytoskeleton of DCs as deduced from inhibitions observed with colchicine (Fig. 4d). Enhancement of adhesion by EOL4G8 also took place with cultured bone marrow-derived murine DCs thus excluding artifacts because of the transformed phenotype of the D2SC/1 cell line (Fig. 4e).

EOL4G8 mAb Enhances Adhesion of Human DCs to Mouse Endothelium in a DC-SIGN-mediated Fashion. EOL4G8 also increases the adhesion of human DCs to the murine endothelioma PY-4.1 (Fig. 5a), although the antibody does not bind human ICAM-2 nor does it stain human DCs (FACS histogram in Fig. 5a). Therefore, the antibody in this case cannot bind both cell surfaces to form a bridge between them. Instead the mechanism seems to be that EOL4G8 binding modifies ICAM-2 in such a way that it becomes more prone to interact with a putative ligand on human DCs that are not LFA-1, as deducted from the lack of inhibition observed with an anti-CD18 mAb that blocks LFA-1-dependent adhesion (Fig. 5b). As shown in Fig. 5b, an anti-DC-SIGN mAb (MR-1) (23) inhibits 40-50% of the EOL4G8-induced adhesion of human DCs to mouse PY-4.1 endothelioma cells. To additionally confirm the involvement of DC-SIGN, a series of experiments was carried out with transfectants in human K562 cells, which stably expressed DC-SIGN (FACS histogram under Figs. 5, c and d) or in equivalent untransfected cells. As it can be seen in Fig. 5c, EOL4G8 mAb intensely promoted the adhesion of the DC-SIGN+ transfectant to PY-4.1 cells, whereas it did not modify the adhesion of the untransfected K562 cells (Fig. 5d). Moreover the mAb against DC-SIGN inhibited >60% of the adhesion of DC-SIGN+ K562 to mouse endothelium. All of these results strongly indicate that EOL4G8 enhances tumor immunity by promoting the adhesion of ICAM-2+ cells to DC-SIGN molecules expressed on DCs.

DISCUSSION

This study shows that in vivo injection of a mAb that recognizes ICAM-2 (CD102) eradicates experimental solid tumors that do not
express ICAM-2. Hence, the antibody required the contribution of endogenous mechanisms to interfere with cancer progression. Ineffectiveness of the antibody in nude and rag2<sup>−/−</sup> mice pointed out an absolute requirement of T cells. Depletion experiments with anti-CD8 mAb clearly showed that CTLs were required for antitumor effects, and this fact correlated with the detection of antitumor-specific CTL activity in EOL4G8-treated mice. mAbs that enhance the antitumor immune response to produce therapeutic immunity have been described. The most potent seem to be anti-CTLA-4 (2), anti-4-1BB (3), and anti-CD40 (4). Each of them acts through different mechanisms that share the activation of a CTL response against the tumor as the final effector mechanism.

ICAM-2 is readily expressed on murine activated T cells but very poorly so on resting T cells. Thus, it was conceivable that EOL4G8 could be providing costimulatory signals to T cells pre-activated through the T-cell receptor. However all of our attempts to show that costimulatory activity for proliferation or cytokine secretion in vitro have failed. Therefore, it is still unresolved whether ICAM-2 artificial ligation with EOL4G8 mAb on T cells would be involved in the observed antitumor effects by direct signals through ICAM-2. ICAM-2 bound by mAbs has not been involved yet in active signaling unlike the case of related molecules such as ICAM-1 (32), ICAM-3 (33), and VCAM-1 (34). The reported intracytoplasmic interactions of ICAM-2 with cytoskeletal proteins (35, 36) may be involved in these phenomena, and are consistent with our observations on the capping and internalization induced by EOL4G8.

CTL activity and the lymphoid infiltration of tumors after systemic treatment with EOL4G8 speak of an activation of the immune system provoked by the antibody in vivo. The presence of granulocytes in the infiltrate is also interesting and resembles to some extent observations in tumors transfected to produce certain cytokines (37) or fas-L (38, 39). Because CT26 is more immunogenic than MC38 (18), the higher efficacy of EOL4G8 treatment on CT26-derived tumors indicates that EOL4G8 amplifies a weak, preexisting immune response. The basal immunogenicity of CT26 cells is best indicated by experiments that show a slower growth of these transplanted tumors in BALB/c mice than in Rag-2<sup>−/−</sup> syngeneic mice.  

4 I. Tirapu et al. submitted for publication.
Carbohydrates attached to ICAM-2 are ligands of the DC-SIGN lectin (10). DC-SIGN on interaction with ICAM-3 has been found instrumental for the early low avidity interactions of DCs and T cells (12). Our results show an enhanced attachment of immature DCs to endothelial cells on incubation with EOL4G8. Because EOL4G8 stains with some degree of selectivity tumor endothelium, it is possible that the mAb favors recruitment of DCs into malignant tissue. Besides it is tempting to speculate that the antibody would modify ICAM-2/DC-SIGN interactions at the immunological synapse between lymphocytes and DCs. Our data with the interspecies adhesion systems, involving human DCs and mouse endothelial cells, strongly suggest that EOL4G8 operates increasing the adhesion of ICAM-2 to DC-SIGN. The involvement of human DC-SIGN is shown both by antibody blocking and by transmission of the activity on transfection of the DC-SIGN-encoding cDNA. Definitive proof of such hypotheses awaits additional characterization on the function of mouse homologues of DC-SIGN (16).

EOL4G8 binds ICAM-2 at an epitope that interferes with LFA-1 binding (an activity that maps to the NH₂-terminal Ig domain of ICAM-2; Refs. 7, 8, 13) but which could up-regulate somehow the binding to DC-SIGN (an activity dependent on the COOH-terminal Ig domain of human ICAM-2 and its attached carbohydrates; Ref. 13).

Peculiar functional properties of the epitope bound by EOL4G8 mAb might be crucial to understand its biological properties. This is supported by our observation that another antibody against ICAM-2 (3C8), which also interferes with adhesion to LFA-1 (Ref. 9; although it binds to a noncompeting epitope), fails to up-regulate DC adhesion to endothelium. A conformational change induced by EOL4G8 in the protein backbone of ICAM-2 or its attached carbohydrates, enhancing its adhesiveness to DC-SIGN, could be the intimate mechanism of action. This is our best-fitting explanation to the observation that EOL4G8 also enhances binding of DCs to immunopurified ICAM-2 attached to plastic. We cannot exclude that other putative ICAM-2-binding lectins might also be involved.

EOL4G8 inhibits angiogenesis of Matrigel implants, but such an effect, although detectable, was very weak in comparison to inhibitions reported for other agents of which the efficacy is entirely dependent on this mechanism (28, 29, 40). An appraisal of the real extent of the contribution of antiangiogenesis to the overall EOL4G8 efficacy is difficult, but this mechanism is not sufficient to cause macroscopic antitumor activity in immunodeficient mice.

As a whole our studies define ICAM-2 as a new target for antibodies mediating antitumor effects through indirect mechanisms that seem to include enhancement of the intrinsic adhesion properties of...
this molecule. In vivo, the injected antibody finds its cognate antigen mainly on activated T cells and on endothelial cells, and is subsequently capable to initiate antigen immune mechanisms that can eradicate established tumors.

ACKNOWLEDGMENTS

We thank Drs. Francisco Sánchez-Madrid, Lieping Chen, Juan José Lasarte, Gloria González, Cheng Qian, Maurizio Bendandi, and Piru Fortes for helpful suggestions and critical reading. We also thank Drs. V. Bautch, A. Mantovani, and P. Riccardi-Castagnoli for their generous gifts of cell lines. Excellent animal facility assistance by Juan Pecarz and Javier Guillen is also acknowledged.

REFERENCES

An Anti-ICAM-2 (CD102) Monoclonal Antibody Induces Immune-mediated Regressions of Transplanted ICAM-2-negative Colon Carcinomas

Ignacio Melero, Izaskun Gabari, Angel L. Corbí, et al.


Updated version
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/62/11/3167

Cited articles
This article cites 39 articles, 16 of which you can access for free at:
http://cancerres.aacrjournals.org/content/62/11/3167.full.html#ref-list-1

Citing articles
This article has been cited by 6 HighWire-hosted articles. Access the articles at:
/content/62/11/3167.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.